Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab HRQoL in Migraine with Comorbidities
NCT04114630Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erenumab in migraine, sponsored by Novartis. Primary endpoint: Change in Migraine-Specific Quality of Life Questionnaire (MSQ 2.1) domains (RFR, RFP, EF) at 12 months. Planned start Oct 2019; status: withdrawn.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04114630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114630.